ABSTRACT Bronchial mucosal biopsy specimens were obtained during fibreoptic bronchoscopy in 30 patients receiving a new oral cephalosporin antibiotic, cefaclor (10 had 250 mg, 10 had 500 mg, and 10 had 1000 mg every eight hours). In 10 patients (from all dosage groups) cefaclor was undetectable in the bronchial mucosa but in every case the serum concentration was low, suggesting incomplete absorption. The mean (SD) bronchial mucosal concentration after 250 mg was 3-78 (1-77) ,ug/g (range 2-1-5-8 pug/g, n = 4), after 500 mg 4-43 (2.04) ug/g (range 2-0-7-1 ,ug/g, n = 8), and after 1000 mg 7*73 (2.76) ug/g (range 5-012-7 ,ug/g, n = 6). A significantly higher concentration in the bronchial mucosa was achieved with 1000 mg than with 250 mg (p < 0.05) or 500 mg (p < 0-025). These concentrations should be effective against Streptococcus pneumoniae, most strains being inhibited below 10 ,ug/ml. The concentrations were within one dilution of the minimal inhibitory concentration for Haemophilus infuenzae, most strains being inhibited below 4 0 Zg/ml. Some strains of H injflenzae will not be inhibited by the concentrations of cefaclor found in the bronchial mucosa, particularly those that are ampicillin resistant.
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Cefaclor is a new oral cephalosporin antibiotic that possesses more activity than cephalexin in vitro against certain organisms, including Haemophilus influenzae, Klebsiella pneumoniae, and Escherichia coli. [1] [2] [3] The most common infecting organisms causing acute bronchial infection in patients with chronic bronchitis are H influenzae and Streptococcus pneumoniae. 4 In recent years several reports have indicated an increasing incidence of the resistance of H influenzae to ampicillin, the prevalence rate being 5-10%.5 This resistance, which may result in treatment failure, is usually ascribed to 18-lactamase enzyme production, but there may also be a degree of inherent resistance.5 Cefaclor retains greater activity against ampicillin resistant H influenzae than the first generation cephalosporins.' 2 6 Early clinical studies have indicated that cefaclor is effective in acute bronchitis and pneumonia caused by susceptible organisms.'-9 The purpose of this study was to evaluate the penetration of cefaclor into bronchial mucosa and to compare the concentrations achieved with the in vitro antibacterial activity of the antibiotic. final volume of biops material 0-3 ml x lower limit of assa sensitivit 0-063 ml * Lower limnit of detection for bronchial level = weight of biopsy material Table 2 Number ofdoses received, the individual and mean (SD) bronchial mucosal weights, serum and bronchial mucosal cefaclor concentratons, and the lower limits ofdetection for the bronchial concentrations in I 0 patients receiving 500 mg cefaclor orally before bronchoscopy In this study bronchial mucosal concentrations are much higher than those found in sputum.21 22 Levison et al2' found a mean concentration of 0-6 ,ug/ml (range 0-3-1 1 ,ug/ml) in six bronchitic patients, but failed to detect it at all in another four patients after 1000 mg cefaclor. Simon and Gatzemeier22 found in bronchitic patients mean peak concentrations of 0-44 (first day) and 0-54 ug/ml (third day) when 500 mg cefaclor was taken four times daily and 0-57 (first day) and 0*54 ,ug/ml (third day) with 1000 mg four times daily, these sputum concentrations being 8-10% of serum levels. Cefaclor may show instability in bronchial secretions in vivo related to temperature, pH, or the protein content.
Microbiological studies of sensitivity to cefaclor have indicated that the minimal inhibitory concentration (MIC) of S pneumoniae ranges from 0.5 to 4 0 ,ug/ml, most strains being inhibited below 1 0 ,ug/Ml. 310 A wide range of susceptibility to H influenzae has been reported, MICs ranging from 0 5 to 16-0 Ag/ml for ampicillin sensitive strains with most inhibited below 4 0 ,ug/ml, and from 0-5 to 64 Zg/ml for ampicillin resistant or,8-lactamase producing strains with most inhibited below 16-0 ,ug/ml. ' 2 6 The bronchial mucosal concentrations achieved in this study by patients with appropriate serum concentrations should be effective against S pneumoniae with all doses used. The concentrations are within one dilution of the MIC for H infuenzae so that not all strains will be inhibited, particularly ampicillin resistant strains. This also applies for Gram negative organisms, which may be implicated in patients with severe bronchial disease-for example, K pneumoniae, E coli (MIC < 8&0 ,g/ml ' 2) . Ultimately the efficacy of an antibiotic for these infections can be assessed only by the clinical response of the patient. The results of this work indicate the need for further studies of efficacy and bioavailability in patients with bronchial infection.
